{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:12:55Z","timestamp":1783739575628,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"publisher","award":["2024JC-YBMS-738"],"award-info":[{"award-number":["2024JC-YBMS-738"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"publisher","award":["2024JC-YBMS-773"],"award-info":[{"award-number":["2024JC-YBMS-773"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzen Municipality","doi-asserted-by":"publisher","award":["SZSM201612097"],"award-info":[{"award-number":["SZSM201612097"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031935","name":"Xi'an Jiaotong University","doi-asserted-by":"publisher","award":["xzy012023125"],"award-info":[{"award-number":["xzy012023125"]}],"id":[{"id":"10.13039\/100031935","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejso.2025.111360","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T01:13:42Z","timestamp":1766106822000},"page":"111360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Recurrence patterns and adjuvant therapy strategies in patients with esophageal squamous cell carcinoma who achieved pathological complete response after neoadjuvant immunochemotherapy: A high-volume retrospective study"],"prefix":"10.1016","volume":"52","author":[{"given":"Jianfei","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlu","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawei","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhentao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2025.111360_bib1","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2025.111360_bib2","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ejso.2025.111360_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004291","article-title":"Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejso.2025.111360_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2022.106680","article-title":"Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE)","volume":"103","author":"Yan","year":"2022","journal-title":"Int J Surg"},{"key":"10.1016\/j.ejso.2025.111360_bib5","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/JS9.0000000000000816","article-title":"Comparison of efficacy and safety between neoadjuvant chemotherapy and neoadjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis","volume":"110","author":"Xu","year":"2024","journal-title":"Int J Surg"},{"key":"10.1016\/j.ejso.2025.111360_bib6","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1245\/s10434-023-14809-1","article-title":"Long-term survival and recurrence patterns in locally advanced esophageal squamous cell carcinoma patients with pathologic complete response after neoadjuvant chemotherapy followed by surgery","volume":"31","author":"Wu","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2025.111360_bib7","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.111360_bib8","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/cncr.20916","article-title":"Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation","volume":"103","author":"Chirieac","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2025.111360_bib9","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1038\/s41591-024-03064-w","article-title":"Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial","volume":"30","author":"Qin","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ejso.2025.111360_bib10","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/s41591-023-02469-3","article-title":"Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial","volume":"29","author":"Yin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ejso.2025.111360_bib11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.athoracsur.2024.02.021","article-title":"Immunotherapy for resectable locally advanced esophageal carcinoma","volume":"118","author":"Fick","year":"2024","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ejso.2025.111360_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2022.106767","article-title":"Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: a systematic review and meta-analysis","volume":"104","author":"Wang","year":"2022","journal-title":"Int J Surg"},{"key":"10.1016\/j.ejso.2025.111360_bib13","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jtcvs.2023.08.056","article-title":"Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study","volume":"167","author":"Yang","year":"2024","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ejso.2025.111360_bib14","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2025.111360_bib15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/SLA.0000000000002670","article-title":"Multi-institutional analysis of recurrence and survival after neoadjuvant chemoradiotherapy of esophageal cancer: impact of histology on recurrence patterns and outcomes","volume":"269","author":"Xi","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2025.111360_bib16","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/SLA.0000000000005619","article-title":"An international cohort study of prognosis associated with pathologically complete response following neoadjuvant chemotherapy versus chemoradiotherapy of surgical treated esophageal adenocarcinoma","volume":"276","author":"Cools-Lartigue","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2025.111360_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221108693","article-title":"Survival benefit of surgery in patients with clinical T4 esophageal cancer who achieved complete or partial response after neoadjuvant chemoradiotherapy or radiotherapy","volume":"14","author":"Gao","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejso.2025.111360_bib18","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/SLA.0b013e3181949e9f","article-title":"Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy","volume":"249","author":"Chao","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2025.111360_bib19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jtho.2024.09.1443","article-title":"Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis","volume":"20","author":"Marinelli","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejso.2025.111360_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1332492","article-title":"Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: a multi-center propensity score match study","volume":"15","author":"Xie","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejso.2025.111360_bib21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12943-024-02006-x","article-title":"Minimal residual disease profiling predicts pathological complete response in esophageal squamous cell carcinoma","volume":"23","author":"Yue","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ejso.2025.111360_bib22","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41467-024-46307-7","article-title":"Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325017883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325017883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:27:41Z","timestamp":1783736861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798325017883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0748798325017883"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.111360","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurrence patterns and adjuvant therapy strategies in patients with esophageal squamous cell carcinoma who achieved pathological complete response after neoadjuvant immunochemotherapy: A high-volume retrospective study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.111360","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111360"}}